BR0214564A - Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos - Google Patents

Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos

Info

Publication number
BR0214564A
BR0214564A BR0214564-2A BR0214564A BR0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A
Authority
BR
Brazil
Prior art keywords
antineoplastic agents
fpt inhibitor
treatment processes
cancer treatment
medicament
Prior art date
Application number
BR0214564-2A
Other languages
English (en)
Portuguese (pt)
Inventor
David L Cutler
Michael L Meyers
Charles Baum
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0214564A publication Critical patent/BR0214564A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0214564-2A 2001-11-30 2002-11-25 Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos BR0214564A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
BR0214564A true BR0214564A (pt) 2004-11-09

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214564-2A BR0214564A (pt) 2001-11-30 2002-11-25 Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN101181269A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
KR20250102088A (ko) 2022-11-09 2025-07-04 메르크 파텐트 게엠베하 선천성 항종양 면역을 유발시키기 위한 면역-자극제로서 Toll-유사 수용체 7 효현제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
EP1448268A2 (en) 2004-08-25
WO2003047697A3 (en) 2003-10-30
US20030185831A1 (en) 2003-10-02
NO20042730L (no) 2004-06-29
CN101181269A (zh) 2008-05-21
MXPA04005207A (es) 2004-08-19
HUP0402401A2 (hu) 2005-03-29
CA2468839A1 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17
CN1617755A (zh) 2005-05-18
ZA200403737B (en) 2005-05-23
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BR0208373A (pt) Inibidores da tirosina cinase
BR0312464A (pt) Inibidores de tirosina quinases
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
PT1420801E (pt) Utilização de fucanos no tratamento de adesões, artrite e psoríase
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 DA RPI 2108 DE 31/05/2011.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4545 (2006.01), A61P 35/00 (2006.01)